摘要:
Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
摘要:
This invention concerns certain 5-(substituted amino) isothiazoles, compounds of Formula I, and salts thereof, where Q is CN, NHCONRaRb, or CONRaRb, where Ra and Rb are defined herein; and R1 is cyclohexyl, adamantan-1-yl, indan-1-yl, phenyl, benzyl, pyridyl, pyridylmethyl, or pyrimidyl, where all aromatic R1 groups are optionally substituted, provided that when R1 is phenyl, then R1 bears at least one non-alkyl substituent, and further provided that R1 is not 4-chloro-3-trichloromethyl-phenyl; The invention also concerns the tautomeric 5-(substituted amino)-isothiazol-3(2H)-ones, and the use of such compounds to treat Hepatitis C infection. It also concerns thiocarbamoyl acetamides, which are synthetic precursors to the isothiazoles.
摘要翻译:本发明涉及某些5-(取代氨基)异噻唑,式I化合物及其盐,其中Q为CN,NHCONR a R b B或CONR 其中R a a和R bb在本文中定义;其中R a,R b和R b都定义如上。 和R 1是环己基,金刚烷-1-基,茚满-1-基,苯基,苄基,吡啶基,吡啶基甲基或嘧啶基,其中所有芳族R 1〜 任选地被取代,条件是当R 1为苯基时,R 1至少具有一个非烷基取代基,并且进一步地,R 1' 不是4-氯-3-三氯甲基 - 苯基; 本发明还涉及互变异构5-(取代氨基) - 异噻唑-3(2H) - 酮,以及这些化合物用于治疗丙型肝炎感染的用途。 它还涉及硫代氨基甲酰基乙酰胺,它们是异噻唑的合成前体。
摘要:
Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
摘要:
Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.